The company may be sacrificing current earnings per share to drive growth. The modest 1.2% dividend yield is unlikely to be attracting many buyers. The company's future earnings are worth investigating, especially considering the strong total shareholder return over the past five years.

Lushang Freda Pharmaceutical Co.,Ltd.'s low P/S ratio is likely due to anticipated poor revenue performance. The company's declining revenue and negative growth forecast compared to the industry's positive outlook justify its low P/S ratio.

Despite declining revenues, investors puzzlingly keep P/S from dropping, a move that appears unsustainable. The company's potential overvaluation via P/S ratio amidst poor revenue outlook suggests a premium might be paid for the stock.

Despite declining revenues, investors are questionable for keeping P/S from dropping, likely affecting the share price negatively. The company may be overvalued given the gloomy revenue outlook, suggesting a premium paid for the stock.

Investors' efforts to maintain the P/S amidst a steady revenue decline seems questionable and unsustainable. The company's potential overvaluation due to the grim revenue prospect hints at investors possibly paying more for the stock.

Despite steady revenue decline, investors are questionably maintaining the P/S ratio, a seemingly unsustainable move that may negatively impact share price. The overvalued P/S ratio indicates a premium payment for the stock amidst a bleak revenue foresight.

Lushang Freda's EPS drop shows market judgment not just on earnings. Current revenue growth implies management prioritizes it over EPS. Price moderation might mean the company's best stock days are past.

The COVID-19 infection rate has peaked in major Chinese cities (such as Beijing, Shanghai, Guangzhou, Shenzhen, and so on.) The number of COVID-19 infections has begun to fall from a high level. What is the progress of the current consumer market recovery now?
How to grasp the investment opportunities in the consumer sector in 2023?
[Food & Beauty]Infection peak has passed. Consumer recovery ahead
Infections...